Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07
(Updated)
Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($2.07), $1.97 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $29 million.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:
- A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized infusion rate (AIR) across all 12 participants in the study
- Evidence of stable, durable expression, with no decline in plateau FVIII levels, in both participants in the 5x1011 vg/kg cohort who have been followed for greater than one year
- A dose response as demonstrated by FVIII expression ranging from 16 to 49 percent, with a mean of 30 percent post 12 weeks in five of the participants in the 2x1012 vg/kg cohort
For earnings history and earnings-related data on Spark Therapeutics (ONCE) click here.